Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Biotechnology

Healthcare
$945.53 -0.90%

-$5.45 today

Market cap
$97.80B
Beta
0.24
P/E (TTM)
14.2
EPS (TTM)
$42.53
Dividend yield
0.60%
52W Low $506.38High $821.11

Volume 0.70M

Average 0.91M

REGN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Regeneron Pharmaceuticals, Inc.NASDAQ: REGN

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 86.6%

Gross margin was 86.6% in Q2 FY2026, up 1.0 pp from a year earlier. On a trailing-twelve-month basis it was 84.9%, down 0.7 pp year over year. Over 3 fiscal years it narrowed by 0.6 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
86.6%+5.1 pp QoQ
Last fiscal yearDec 2025
85.4%-0.8 pp YoY
LTMJun 2026
84.9%-0.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.0 pp——
1 year-0.8 pp——
3 years-0.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
85.4%
Year-over-year change
-0.8pp

Gross Margin vs competitors

How REGN compares with its peers on the latest reported figures

  • REGN's LTM Jun 2026 gross margin of 84.9% is the 3rd highest of the 9 companies compared; the peer median is 78.0%.
  • Its year-over-year change of -0.7 pp is the 3rd highest of 8, against a peer median of -2.3 pp.
  • Over three fiscal years its change of -0.6 pp compares with a peer median of -2.2 pp.
REGN Competitors Peer median
Gross Margin for REGN and competitors
Company Period LTM level YoY 3-year change
GMABGenmab A/SLTM Jun 202693.0% —-8.3 pp
OCULOcular Therapeutix, Inc.LTM Mar 202687.2% -3.4 pp-3.9 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202684.9% -0.7 pp-0.6 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
GILDGilead Sciences, Inc.LTM Jun 202679.6% +1.1 pp-0.4 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202676.5% -16.8 pp+13.5 pp
NVSNovartis AGLTM Jun 202674.4% -1.8 pp+1.7 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
BIIBBiogen Inc.LTM Jun 202667.7% -4.8 pp-7.1 pp
Peer median (excluding REGN) 78.0%-2.3 pp-2.2 pp

Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.07B12.17B13.12B14.2B14.34B
Cost of Revenue2.72B1.71B2.24B1.97B2.1B
Gross Profit13.35B10.47B10.87B12.23B12.24B
Gross Margin83.1%86.0%82.9%86.1%85.4%
Research & Development2.62B3.06B3.99B5.23B5.85B
Selling, General & Admin1.82B2.12B2.54B2.95B2.7B
Operating Expenses4.4B5.08B6.52B8.24B8.66B
Depreciation & Amortization286.2M341.4M421M482.9M543.7M
EBITDA9.67B5.26B4.69B5.32B5.82B
EBITDA Margin60.2%43.2%35.8%37.4%40.6%
Operating Income8.95B5.39B4.35B3.99B3.58B
Operating Margin55.7%44.2%33.2%28.1%24.9%
Interest Income0160.1M495.9M711.4M716.8M
Interest Expense57.3M59.4M73M55.2M43.8M
Other Income / Expenses379M(526.8M)(149.3M)789.2M1.65B
Income Before Tax9.33B4.86B4.2B4.78B5.23B
Pre-Tax Margin58.0%39.9%32.0%33.7%36.5%
Income Tax Expense1.25B520.4M245.7M367.3M725.8M
Net Income8.08B4.34B3.95B4.41B4.5B
Net Margin50.2%35.6%30.1%31.1%31.4%
EPS (Basic)76.4040.5137.0540.9043.07
EPS (Diluted)71.9738.2234.7738.3441.48
Weighted Avg Shares105.7M107.1M106.7M107.9M104.6M
Weighted Avg Shares (Diluted)112.2M113.5M113.7M115.1M108.6M

Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Intrinsic Alpha fair value

Locked

Current Price

$945.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.